## Michela Meregaglia

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7225214/publications.pdf

Version: 2024-02-01

687363 752698 21 406 13 20 citations h-index g-index papers 21 21 21 783 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Efficacy and Safety of Ferric Carboxymaltose and Other Formulations in Iron-Deficient Patients: A Systematic Review and Network Meta-analysis of Randomised Controlled Trials. Clinical Drug Investigation, 2016, 36, 177-194.	2.2	51
2	Health and Economic Outcomes of Introducing the New MenB Vaccine (Bexsero) into the Italian Routine Infant Immunisation Programme. PLoS ONE, 2015, 10, e0123383.	2.5	39
3	Mudâ€Bath Therapy in Addition to Usual Care in Bilateral Knee Osteoarthritis: An Economic Evaluation Alongside a Randomized Controlled Trial. Arthritis Care and Research, 2017, 69, 966-972.	3.4	34
4	A systematic literature review of health state utility values in head and neck cancer. Health and Quality of Life Outcomes, 2017, 15, 174.	2.4	34
5	The Use of Patient-Reported Outcome Measures in Rare Diseases and Implications for Health Technology Assessment. Patient, 2021, 14, 485-503.	2.7	31
6	An EQ-5D-5L value set for Italy using videoconferencing interviews and feasibility of a new mode of administration. Social Science and Medicine, 2022, 292, 114519.	3.8	29
7	The short-term economic burden of gestational diabetes mellitus in Italy. BMC Pregnancy and Childbirth, 2018, 18, 58.	2.4	28
8	A comparison of EuroQol 5-Dimension health-related utilities using Italian, UK, and US preference weights in a patient sample. ClinicoEconomics and Outcomes Research, 2016, 8, 267.	1.9	22
9	Economic evaluations of follow-up strategies for cancer survivors: a systematic review and quality appraisal of the literature. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 913-929.	1.4	17
10	Patient-reported outcome measures in core outcome sets targeted overlapping domains but through different instruments. Journal of Clinical Epidemiology, 2021, 136, 26-36.	5.0	17
11	Hospital Burden and Gastrointestinal Surgery in Inflammatory Bowel Disease Patients in Italy: A Retrospective Observational Study. Journal of Crohn's and Colitis, 2015, 9, 853-862.	1.3	15
12	Eliciting Preferences for Clinical Follow-Up in Patients with Head and Neck Cancer Using Best-Worst Scaling. Value in Health, 2017, 20, 799-808.	0.3	15
13	The use of intensive radiological assessments in routine surveillance after treatment for head and neck cancer: An economic evaluation. European Journal of Cancer, 2018, 93, 89-98.	2.8	14
14	Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia. European Journal of Health Economics, 2019, 20, 181-193.	2.8	14
15	Mapping' Health State Utility Values from Non-preference-Based Measures: A Systematic Literature Review in Rare Diseases. Pharmacoeconomics, 2020, 38, 557-574.	3.3	14
16	A scoping review of core outcome sets and their †mapping†onto real-world data using prostate cancer as a case study. BMC Medical Research Methodology, 2020, 20, 41.	3.1	13
17	The estimation of health state utility values in rare diseases: overview of existing techniques. International Journal of Technology Assessment in Health Care, 2020, 36, 469-473.	0.5	8
18	Consideration of quality of life in the health technology assessments of rare disease treatments. European Journal of Health Economics, 2022, 23, 645-669.	2.8	7

#	Article	IF	CITATIONS
19	Low socioâ€economic conditions and prematurityâ€related morbidities explain healthcare use and costs for 2â€yearâ€old very preterm children. Acta Paediatrica, International Journal of Paediatrics, 2020, 109, 1791-1800.	1.5	3
20	Health and economic outcomes of two different follow up strategies in effectively cured advanced head and neck cancer patients Journal of Clinical Oncology, 2015, 33, TPS6625-TPS6625.	1.6	1
21	Feasibility of Deriving Health State Utilities in Mycosis Fungoides Cutaneous T-Cell Lymphoma Using Mapping Algorithms. PharmacoEconomics - Open, 2022, , 1.	1.8	0